28th Feb 2005 15:15
28 February 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that it was notified on 28 February 2005 under Sections198 to 202 of the Companies Act that FMR Corp. and its direct and indirectsubsidiaries and Fidelity International Limited and its direct and indirectsubsidiaries, both being non-beneficial holders, held solely for investmentpurposes, in aggregate 28,775,507 ordinary shares of ‚£0.05p each in the capitalof the Company. These holdings represent 5.87 per cent of the issued ordinaryshare capital of the Company.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld +44 1256 894 160 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI) and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.comENDRelated Shares:
Shire